CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug ...

CVS Caremark has granted preferred formulary status to both Novo Nordisk's Wegovy and Eli Lilly's Zepbound and Foundayo. This decision reverses Wegovy's prior commercial advantage within CVS ...

Please provide your email address to receive an email when new articles are posted on . CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national ...

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...

CVS Health Corporation (NYSE:CVS) is one of the Best Undervalued Stocks to Buy Under $100. On May 5, the company announced that its pharmacy benefit arm is updating its commercial formularies ...

By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...

CVS Caremark is putting Eli Lilly’s obesity drug Zepbound back on some commercial formularies starting Oct. 1, reversing a mid-2025 decision that had nudged many patients toward rival GLP-1 ...

WOONSOCKET, R.I., Jan. 15, 2019 /PRNewswire/ -- CVS Health (NYSE: CVS) announced today that Walmart has opted to leave the CVS Caremark pharmacy benefit management (PBM) commercial and Managed ...

CVS Health has announced a significant expansion of its coverage for Eli Lilly's weight-loss medications, confirming it will ...